专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

EP2329820A4 PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF 有权
标题翻译：药物组合物高血压和代谢综合征和其使用的治疗
公开(公告)号：EP2329820A4
公开(公告)日：2011-11-02
申请号：EP09799935
申请日：2009-07-23
申请人： LUNAN PHARM GROUP CORP
发明人： ZHAO ZHIQUAN
IPC分类号： A61K31/4422 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/4439 , A61K31/505 , A61P3/00 , A61P3/06 , A61P3/10 , A61P9/12
CPC分类号： A61K9/2059 , A61K9/1652 , A61K9/2054 , A61K9/209 , A61K9/4866 , A61K31/4422 , A61K31/4439 , A61K31/505 , A61K2300/00

52. 发明公开

EP2380562A1 A CONTROLLED-RELEASED OSMOTIC PUMP TABLET WITH LUBRICATING LAYER AND THE PREPARATION THEREOF 审中-公开
标题翻译：具有控释和滑动层和生产渗透泵片
公开(公告)号：EP2380562A1
公开(公告)日：2011-10-26
申请号：EP09832823.0
申请日：2009-12-16
申请人： Beijing Kexin Bicheng Biomedical Technology Development Co., Ltd.
发明人： JIANG, Haisong , WANG, Jingang
IPC分类号： A61K9/22 , A61K9/28 , A61K31/4422 , A61P9/10
CPC分类号： A61K9/0004 , A61K31/4422
摘要： The invention relates to the field of pharmaceutical preparation, in particular to a bilayer osmotic pump controlled-release tablet preparation and a preparation method thereof. Said bilayer osmotic pump controlled-release tablet comprises a conventional tablet core, release control layer(s) and drug release hole(s), wherein one or more lubricating layer structure(s) is/are disposed between the tablet core and the release control layer(s). The lubricating layer(s) is/are present in an amount of from 0.5% to 6% based on the weight of the bilayer tablet core. The lubricating layer(s) rapidly hydrates once in contact with water to form the favorable lubricating liquor between the tablet core and the release control layer(s), hence reducing the shear force between the drug-containing layer(s) and the release control layer(s), whereby the drug-containing layer(s) is/are pushed out completely by the propellant layer(s) to reach a drug release percent of nearly 100%. This solves the problem of the incomplete drug release due to the dead angle generated by the drug-containing layer of a conventional bilayer osmotic pump controlled-release tablet during the release procedure. This technique ensures the superior bioavailability of the bilayer osmotic pump controlled-release tablet as prepared.
摘要翻译：本发明涉及药物制剂的领域中，特别是双层渗透泵控释片制剂及其制备方法。所述双层渗透泵控释片包括常规的片剂核心，释放控制层（一个或多个）和药物释放孔（一个或多个），worin一种或多种润滑层结构（S）是被所述片芯和释放控制之间设置/ 层（S）。润滑层（多个）/存在于基于所述双层片剂芯的重量的从0.5％至6％的量存在。润滑层（一个或多个）在与水接触时快速水合一次以形成片芯和释放控制层（一个或多个）之间的良好的润滑液，因此减少了含有药物的层（S）和释放控制之间的剪切力层（S），由此，药物含有层（多个）/被完全推出由推进剂层（一个或多个）电话，以达到接近100％的药物释放百分比。这解决了问题的不完全的药物释放由于释放过程期间由常规的双层渗透泵控释片剂的药物含有层中产生的死角。该技术保证了双层渗透泵控释片剂的生物利用度优异作为制备。

53. 发明公开

EP2322177A1 Use of a preparation based on nifedipine for treating vaginismus 失效
标题翻译： Verwendung einer Zusammensetzung aus Nifedipin zur Behandlung von Vaginismus
公开(公告)号：EP2322177A1
公开(公告)日：2011-05-18
申请号：EP10190564.4
申请日：2010-11-09
申请人： Antropoli, Carmine
发明人： Antropoli, Carmine
IPC分类号： A61K31/4422 , A61P15/02 , A61P21/02 , A61K9/00 , A61K31/23 , A61K31/232 , A61K31/4168 , A61K31/728 , A61K38/39 , A61K45/06
CPC分类号： A61K31/4422 , A61K9/0034 , A61K9/0036 , A61K9/02 , A61K9/06 , A61K31/23 , A61K31/232 , A61K31/4168 , A61K31/728 , A61K38/39 , A61K45/06 , A61K47/46 , A61K2300/00
摘要： The local use of Nifedipine in synergistic association with one or more active principles and eudermic ingredients chosen in the group constituted by almond oil, hyaluronic acid, vitamin A (retinyl palmitate), allantoin and elastin, acts positively on the pathological condition, relaxing the muscular tension and at the same time preventing onset of undesirable side effects.
摘要翻译：当地使用硝苯地平与由杏仁油，透明质酸，维生素A（视黄醇棕榈酸酯），尿囊素和弹性蛋白组成的组中选择的一种或多种活性成分和精神成分协同协作，对病理状况产生积极的作用，使肌肉松弛并且同时防止发生不期望的副作用。

54. 发明公开

EP2300012A2 METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY 审中-公开
标题翻译：方法周围神经感觉丧失使用连接烟碱型乙酰胆碱受体的治疗效果
公开(公告)号：EP2300012A2
公开(公告)日：2011-03-30
申请号：EP09751248.7
申请日：2009-05-15
申请人： University of South Florida
发明人： ZESIEWICZ, Theresa, A. , SULLIVAN, Kelly, L. , RAMSEY, John, Edward
IPC分类号： A61K31/498 , A61K31/4422 , A61K31/135 , A61K31/55 , A61P25/28 , A61P25/00
CPC分类号： A61K31/135 , A61K31/4422 , A61K31/498 , A61K31/55
摘要： Methods for treatment of peripheral nerve sensory loss are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.

55. 发明公开

EP1587792A4 STABLE AMORPHOUS AMLODIPINE CAMSYLATE, PROCESS FOR PREPARING SAME AND COMPOSITION FOR ORAL ADMINISTRATION THEREOF 有权
标题翻译：稳定的非晶AMLODIPINCAMSYLAT，方法ITS和组合物及其口服
公开(公告)号：EP1587792A4
公开(公告)日：2011-03-09
申请号：EP04705547
申请日：2004-01-27
申请人： HANMI HOLDINGS CO LTD
发明人： MOON YOUNG HO , KIM NAM DU , LEE KYUNG IK , LEE GWAN SUN , WOO JONG SOO , CHANG YOUNG KIL
IPC分类号： A61K31/4422 , C07D211/84 , A61P9/10 , A61P9/12 , C07D211/90
CPC分类号： C07D211/90

56. 发明公开

EP2253318A4 IMPROVEMENT OF DISSOLVABILITY OF PREPARATION CONTAINING OLMESARTAN MEDOXOMIL 有权
标题翻译：与奥美沙坦酯制剂的改进有解
公开(公告)号：EP2253318A4
公开(公告)日：2011-02-23
申请号：EP09719057
申请日：2009-03-02
申请人： DAIICHI SANKYO CO LTD
发明人： YADA SHUICHI , YANO HIDEKI , NAGAIKE TSUYOSHI , YOKOI MISATO
IPC分类号： A61K31/4422 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/4178 , A61K31/549 , A61K47/04 , A61K47/12 , A61K47/22 , A61K47/38 , A61P9/00 , A61P9/12 , A61P43/00
CPC分类号： A61K47/02 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/4178 , A61K31/44 , A61K31/4418 , A61K31/4422 , A61K31/54 , A61K31/549 , A61K2300/00

57. 发明公开

EP2077994A4 CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF 审中-公开
标题翻译：结晶的无水S - （ - ） - AMLODIPINADIPINSÄURESALZ和方法及其
公开(公告)号：EP2077994A4
公开(公告)日：2010-12-15
申请号：EP07833643
申请日：2007-10-26
申请人： CJ CHEILJEDANG CORP
发明人： CHO IL HWAN , YOUN YONG SIK , SONG SEOG BEOM , LIM DONG KWON
IPC分类号： C07D211/90 , A61K31/4422
CPC分类号： C07D211/90
摘要： Disclosed are crystalline S-(−)-amlodipine adipic acid salt anhydrous and a preparation method thereof. The crystalline S-(−)-amlodipine adipic acid salt anhydrous exhibits excellent physical and chemical properties including non-hygroscopicity, solubility, thermal stability, and photostability, and is superior in formulation processability and long-term storage safety.

58. 发明授权

EP1765342B1 PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE BESILATE AND LISINOPRIL DIHYDRATE AND PROCESS FOR THE PREPARATION THEREOF 有权转让
标题翻译：药物组合物苯磺酸氨氯地平LISINOPRILDIHYDRAT及其制造方法
公开(公告)号：EP1765342B1
公开(公告)日：2010-11-03
申请号：EP05751188.3
申请日：2005-06-09
申请人： Richter Gedeon Nyrt.
发明人： KELEN, Ákos
IPC分类号： A61K31/4422 , A61K31/401
CPC分类号： A61K31/401 , A61K31/4422 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition containing 0.3-30 wt % (m/m) of amlopidine besilate and 0.1-75 wt %(m/m) of lisinopril dihydrate as active ingredients in admixture with one or more excipient(s) commonly used in the pharmaceutical industry with the proviso, said excipient is other than a calcium salt of phosphoric acid. A process for the preparation of the above composition is also within the scope of the invention.

59. 发明公开

EP2243483A1 Amlodipine salt compositions for topical application 审中-公开
标题翻译：用于局部应用的氨氯地平盐组合物
公开(公告)号：EP2243483A1
公开(公告)日：2010-10-27
申请号：EP10160506.1
申请日：2010-04-20
申请人： Rabin, Bennie
发明人： Rabin, Bennie
IPC分类号： A61K31/4422 , A61K9/00 , A61P9/00 , A61P17/02
CPC分类号： A61K31/4422 , A61K9/0014
摘要： The present application relates to a topical composition comprising one or more amlodipine salts for the treatment of a circulatory condition, such as Raynaud's phenomenon or chilblains. The present application also relates to the use of one or more amlodipine salts to prepare a topical composition for the treatment of a circulatory condition.
摘要翻译：本申请涉及包含一种或多种氨氯地平盐用于治疗循环状况如雷诺现象或冻疮的局部用组合物。本申请还涉及一种或多种氨氯地平盐用于制备用于治疗循环疾病的局部用组合物的用途。

60. 发明公开

EP2240163A1 PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND VALSARTAN 审中-公开
标题翻译：氨氯地平缬沙坦药物组合物
公开(公告)号：EP2240163A1
公开(公告)日：2010-10-20
申请号：EP08738366.7
申请日：2008-02-21
申请人： Lupin Limited
发明人： KUTE, Anirudha, Bhagirath , MALEWAR, Nikhil, Prabhakar , AVACHAT, Makarand, Krishnakumar
IPC分类号： A61K9/20 , A61K31/41 , A61K31/4422
CPC分类号： A61K9/2054 , A61K31/41 , A61K31/4422 , A61K2300/00
摘要： A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters of a 90% Confidence Interval for AUC which is between 80% and 125%, and a 90% Confidence Interval for Cmax, which is between 80% and 125%.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式